ALX Oncology Holdings (ALX Oncology Holdings) EPS (Diluted) : $-3.74 (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is ALX Oncology Holdings EPS (Diluted)?

ALX Oncology Holdings's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.92. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.74.

ALX Oncology Holdings's EPS (Basic) for the three months ended in Dec. 2023 was $-0.92. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.74.

ALX Oncology Holdings's EPS without NRI for the three months ended in Dec. 2023 was $-0.92. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.74.

During the past 3 years, the average EPS without NRIGrowth Rate was -11.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was -42.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 6 years, ALX Oncology Holdings's highest 3-Year average EPS without NRI Growth Rate was -11.00% per year. The lowest was -51.20% per year. And the median was -49.00% per year.

ALX Oncology Holdings EPS (Diluted) Historical Data

The historical data trend for ALX Oncology Holdings's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ALX Oncology Holdings EPS (Diluted) Chart

ALX Oncology Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Diluted)

Get a 7-Day Free Trial

-1.06

-2.76

-2.07

-3.03

-3.74

ALX Oncology Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EPS (Diluted)	Get a 7-Day Free Trial															-0.75	-0.74	-0.84	-1.24	-0.92

Competitive Comparison of ALX Oncology Holdings's EPS (Diluted)

For the Biotechnology subindustry, ALX Oncology Holdings's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ALX Oncology Holdings's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ALX Oncology Holdings's PE Ratio distribution charts can be found below:

* The bar in red indicates where ALX Oncology Holdings's PE Ratio falls into.

ALX Oncology Holdings EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

ALX Oncology Holdings's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-160.805	-	0)	/	42.988
	=	-3.74

ALX Oncology Holdings's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-45.472	-	0)	/	49.062
	=	-0.93

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.74

ALX Oncology Holdings (NAS:ALXO) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

ALX Oncology Holdings EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of ALX Oncology Holdings's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

ALX Oncology Holdings (ALX Oncology Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ALX Oncology Holdings Inc (NAS:ALXO) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

323 Allerton Avenue, South San Francisco, CA, USA, 94080

Website

https://www.alxoncology.com

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Executives

Shelly Pinto	officer: VP, Finance and CAO	866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Peter S Garcia	officer: Chief Financial Officer	ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Sophia Randolph	officer: Chief Medical Officer	C/O ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Jaume Pons	director, officer: President and CEO	C/O ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
J. Scott Garland	director	210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Itziar Canamasas	director	C/O ALX ONCOLOGY HOLDINGS INC, 323 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
Jason Lettmann	director, 10 percent owner	C/O RA PHARMACEUTICALS, INC., 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Lsv Associates, Llc	10 percent owner	2884 SAND HILL ROAD, SUITE 121, MENLO PARK CA 94025
G. Walmsley Graham	director	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Goodman Corey S	director, 10 percent owner, other: Executive Chairman	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Rekha Hemrajani	director	3928 POINT EDEN WAY, HAYWARD CA 94545
Venbio Global Strategic Fund, L.p.	10 percent owner, other: See Remarks	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Vivo Opportunity Fund, L.p.	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Vivo Opportunity, Llc	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Steffen Pietzke	officer: VP Fin & Chief Acct Officer	C/O ENOVIX CORPORATION, 3501 W. WARREN AVENUE, FREMONT CA 94538